Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses

Comparison of antibody levels against human papillomavirus after vaccination found highest antibody levels against HPV16/18 after bivalent vaccination and against HPV6/11/31/33/45/52/58 after nonavalent vaccination. Antibodies against nonvaccine types were also found (HPV31/33/35/45 or 58 after bivalent; HPV35 after nonavalent vaccine). For head-to-head comparison of human papillomavirus (HPV) antibody levels induced by different vaccines, 25-year-old vaccine-naive women were given either the bivalent (n = 188) or the nonavalent HPV vaccine (n = 184). Six months after vaccination antibodies against pseudovirions from 17 different HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/73) were measured. Antibodies against HPV16/18 were higher after bivalent HPV vaccination (mean international units [IU] 1140.1 and 170.5 for HPV16 and 18, respectively) than after nonavalent vaccination (265.1 and 22.3 IUs, respectively). The bivalent vaccine commonly induced antibodies against the nonvaccine HPV types 31/33/35/45 or 58. The nonavalent vaccine induced higher antibodies against HPV6/11/31/33/45/52/58 and 35.

Automated summary

The study compared antibody levels against human papillomavirus after different vaccinations. The findings showed that bivalent vaccination resulted in higher levels of antibodies against HPV16/18, while nonavalent vaccination resulted in higher levels of antibodies against HPV6/11/31/33/45/52/58.